Pregnant women with hepatitis c get new hope in drug trial
NCT ID NCT07040319
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study is testing the safety and drug levels of glecaprevir/pibrentasvir, a hepatitis C treatment, in 30 pregnant women with or without HIV. The goal is to see how the drug works during pregnancy and to monitor the health of both mothers and their infants up to 10 weeks after birth. It is an early-phase trial, so results will help guide future treatment options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glecaprevir/pibrentasvir (a combination antiviral drug)
What this could lead to
If successful, this could provide a safe way to treat hepatitis C during pregnancy, potentially preventing mother-to-child transmission and improving outcomes for both mother and baby.
What could go wrong
This is an early-phase study with only 30 participants, so results may not apply to all pregnant women. There are also unknown risks to the fetus and infant, and the treatment may not work as well in those with HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor College of Medicine//Texas Children's Hospital
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Bronx-Lebanon Hospital Center
RECRUITINGThe Bronx, New York, 10457, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
David Geffen School of Medicine at UCLA
NOT_YET_RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jacobi Medical Center
NOT_YET_RECRUITINGThe Bronx, New York, 10461, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johns Hopkins University Baltimore
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lurie Children's Hospital of Chicago
RECRUITINGChicago, Illinois, 60614, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SUNY Stony Brook
RECRUITINGStony Brook, New York, 11794, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
USC LA
RECRUITINGLos Angeles, California, 90089, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Univ. of Florida Jacksonville
RECRUITINGJacksonville, Florida, 32209, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado Denver
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••